From: Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Adverse events | Grade 1–2 | Grade 3 | Grade 4 |
---|---|---|---|
Fatigue | 23 (65.7%) | 1 (2.9%) | Â |
Nausea | 20 (57.1%) | Â | Â |
Anorexia | 11 (31.4%) | Â | Â |
Vomiting | 11 | 1 | Â |
Edema | 10 (28.6%) | Â | Â |
Anemia | 8 (22.9%) | 1 | Â |
Diarrhea | 8 | Â | Â |
Rash | 8 | 1 | Â |
Shortness of breath | 7 (20%) | Â | Â |
Constipation | 5 (14.3%) | Â | Â |
Thrombocytopenia | 4 (11.4%) | Â | Â |
Fever | Â | 1 | Â |
Hypoglycemia | Â | 1 | Â |